[1]郑磊,温佳敏,张国明.葡萄膜黑色素瘤的药物治疗研究现状[J].眼科新进展,2018,38(2):188-192.[doi:10.13389/j.cnki.rao.2018.0043]
　ZHENG Lei,WEN Jia-Min,ZHANG Guo-Ming.Research advances in the treatment for uveal melanoma[J].Recent Advances in Ophthalmology,2018,38(2):188-192.[doi:10.13389/j.cnki.rao.2018.0043]
点击复制

葡萄膜黑色素瘤的药物治疗研究现状/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年2期
页码:
188-192
栏目:
文献综述
出版日期:
2018-02-05

文章信息/Info

Title:
Research advances in the treatment for uveal melanoma
作者:
郑磊; 温佳敏; 张国明
518040　广东省深圳市，深圳市眼科医院，深圳眼科学重点实验室，深圳大学眼视光学院（郑磊，张国明）；510060　广东省广州市，眼科学国家重点实验室，中山大学中山眼科中心（温佳敏）
Author(s):
ZHENG Lei; WEN Jia-Min; ZHANG Guo-Ming
Shenzhen Eye Hospital，Shenzhen Key Laboratory of Ophthalmology，Shenzhen University Health Science Center(ZHENG Lei，ZHANG Guo-Ming)，Shenzhen 518040，Guangdong Province，China；The State Key Laboratory of Ophthalmology，Zhongshan Ophthalmic Center，Sun Yat-sen University (WEN Jia-Min)，Guangzhou 510060，Guangdong Province，China
关键词:
葡萄膜黑色素瘤; 药物治疗; 临床试验
Keywords:
uveal melanoma; medication; clinical trials
分类号:
R773
DOI:
10.13389/j.cnki.rao.2018.0043
文献标志码:
A
摘要:
葡萄膜黑色素瘤（uveal melanoma，UM）是成人眼内最常见的恶性肿瘤，虽然近30 a来涌现出许多局部治疗方法，但患者的生存率一直无明显改善，主要原因是缺乏UM的治疗药物，尤其是抑制转移的药物。国外学者针对UM的药物治疗已经开展了大量的临床试验，我国目前仍然采用传统的眼球摘除术治疗UM，缺乏相应的临床药物研究。本文对国内外开展的UM临床药物试验展开综述，以期为眼科医师或肿瘤科医师提供治疗UM的新思路。
Abstract:
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults.Despite the availability of local treatment modalities，the survival rates of patients with UM have not improved in 30 years.And the main reason is lack of therapeutic drugs for UM，especially agents that inhibit tumor metastasis.Foreign researchers have carried out extensive clinical trials on the agents，but traditional ocular enucleation has been performed for the treatment of UM without any clinical drug tests in China.This paper will give a review on these clinical trials abroad，hoping to provide insight in the treatment of UM for domestic ophthalmologists and oncologist.

参考文献/References:

［1］　SHOUSHTARI AN，CARVAJAL RD.Treatment of uveal melanoma［J］.Cancer Treat Res，2016，167：281-293.
［2］　SPAGNOLO F，CALTABIANO G，QUEIROLO P.Uveal melanoma［J］.Cancer Treat Rev，2012，38(5)：549-553.
［3］　LI ZH，LI XM，YANG D，XU G，ZHOU YY，WU SH，et al.Effect of radiotherapy combined with temozolomide on cerebral glioblastoma［J］.J Xinxiang Med Univ，2015，32(6)：529-532，536.
李子煌，李先明，杨东，徐钢，周亚燕，吴事海，等.放射治疗联合替莫唑胺治疗脑胶质母细胞瘤疗效观察［J］.新乡医学院学报，2015，32(6)：529-532，536.
［4］　BEDIKIAN AY，PAPADOPOULOS N，PLAGER C，ETON O，RING S.Phase II evaluation of temozolomide in metastatic choroidal melanoma［J］.Melanoma Res，2003，13(3)：303-306.
［5］　LEYVRAZ S，PIPERNO-NEUMANN S，SUCIU S，BAURAIN JF，ZDZIENICKI M，TESTORI A，et al.Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021)：a multicentric randomized trial［J］.Ann Oncol，2014，25(3)：742-746.
［6］　HOMSI J，BEDIKIAN AY，PAPADOPOULOS NE，KIM KB，HWU WJ，MAHONEY SL，et al.Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma［J］.Melanoma Res，2010，20(6)：507-510.
［7］　KIVELA T，SUCIU S，HANSSON J，KRUIT WH，VUORISTO MS，KLOKE O，et al.Bleomycin，vincristine，lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2 b for metastatic uveal melanoma［J］.Eur J Cancer，2003，39(8)：1115-1120.
［8］　O’NEILL PA，BUTT M，ESWAR CV，GILLIS P，MARSHALL E.A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma［J］.Melanoma Res，2006，16(3)：245-248.
［9］　FLAHERTY KT，LEE SJ，ZHAO F，SCHUCHTER LM，FLAHERTY L，KEFFORD R，et al.Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma［J］.J Clin Oncol，2013，31(3)：373-379.
［10］　HAN C，YOU XH，NIE N，SONG Y.Research advances in tumor immunotherapy［J］.J Shanxi Med，2015，4(44)：502-503.
韩策，尤向辉，聂娜，宋扬.肿瘤免疫治疗研究进展［J］.陕西医学杂志，2015，44(4)：502-503.
［11］　MINN AJ.Interferons and the immunogenic effects of cancer therapy［J］.Trends Immunol，2015，36(11)：725-737.
［12］　LANE AM，EGAN KM，HARMON D，HOLBROOK A，MUNZ-ENRIDER JE，GRAGOUDAS ES.Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis［J］.Ophthalmology，2009，116(11)：2206-2212.
［13］　RICHTIG E，LANGMANN G，SCHLEMMER G，MULLNER K，PAPAEFTHYMIOU G，BERGTHALER P，et al.Safety and efficacy of interferon alfa-2 b in the adjuvant treatment of uveal melanoma［J］.Ophthalmologe，2006，103(6)：506-511.
［14］　WU XT，PAN L，TANG CZ.Research advances in monoclonal antibody of anticancer drugs and its market dynamics［J］.J Xinxiang Med Univ，2011，28(4)：520-523.
吴晓彤，潘磊，唐超智.单克隆抗体抗肿瘤药物研究进展及其市场动态［J］.新乡医学院学报，2011，28(4)：520-523.
［15］　GRAZIANI G，TENTORI L，NAVARRA P.Ipilimumab：a novel immunostimulatory monoclonal antibody for the treatment of cancer［J］.Pharmacol Res，2012，65(1)：9-22.
［16］　DANIELLI R，RIDOLFI R，CHIARION-SILENI V，QUEIROLO P，TESTORI A，PLUMMER R，et al.Ipilimumab in pretreated patients with metastatic uveal melanoma：safety and clinical efficacy［J］.Cancer Immunol Immunother，2012，61(1)：41-48.
［17］　ZIMMER L，VAUBEL J，MOHR P，HAUSCHILD A，UTIKAL J，SIMON J，et al.Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma［J］.PLoS One，2015，10(3)：e0118564.
［18］　LUKE JJ，CALLAHAN MK，POSTOW MA，ROMANO E，RAMAIYA N，BLUTH M，et al.Clinical activity of ipilimumab for metastatic uveal melanoma：a retrospective review of the Dana-Farber Cancer Institute，Massachusetts General Hospital，Memorial Sloan-Kettering Cancer Center，and University Hospital of Lausanne experience［J］.Cancer，2013，119(20)：3687-3695.
［19］　HARBOUR JW.The genetics of uveal melanoma：an emerging framework for targeted therapy［J］.Pigment Cell Melanoma Res，2012，25(2)：171-181.
［20］　SHOUSHTARI AN，CARVAJAL RD.GNAQ and GNA11 mutations in uveal melanoma［J］.Melanoma Res，2014，24(6)：525-534.
［21］　PATEL M，SMYTH E，CHAPMAN PB，WOLCHOK JD，SCHWARTZ GK，ABRAMSON DH，et al.Therapeutic implications of the emerging molecular biology of uveal melanoma［J］.Clin Cancer Res，2011，17(8)：2087-2100.
［22］　CARVAJAL RD，SOSMAN JA，QUEVEDO JF，MILHEM MM，JOSHUA AM，KUDCHADKAR RR，et al.Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma：a randomized clinical trial［J］.JAMA，2014，311(23)：2397-2405.
［23］　CARVAJAL RD，SCHWARTZ GK，MANN H，SMITH I，NATHAN PD.Study design and rationale for a randomised，placebo-controlled，double-blind study to assess the efficacy of selumetinib (AZD6244；ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)［J］.BMC Cancer，2015，15：467.
［24］　FALCHOOK GS，LEWIS KD，INFANTE JR，GORDON MS，VOGELZANG NJ，DEMARINI DJ，et al.Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma：a phase 1 dose-escalation trial［J］.Lancet Oncol，2012，13(8)：782-789.
［25］　SUN J，LI XR.Anti-VEGF strategies to control ocular neovascularization［J］.Rec Adv Ophthalmol，2008，28(1)：65-68.
孙靖，李筱荣.靶向血管内皮生长因子治疗眼新生血管的研究进展［J］.眼科新进展，2008，28(1)：65-68.
［26］　FU T，WEI WB，WANG Y，LIU XC.Clinical significance of serum level of VEGF in uveal melanoma［J］.Chin Ophthal Res，2005，23(6)：604-606.
傅涛，魏文斌，王阳，刘小超.葡萄膜黑色素瘤患者血清血管内皮生长因子浓度及临床意义［J］.眼科研究，2005，23(6)：604-606.
［27］　BAI HL，LIU Q，WEN J，WU XL.Association of serum vascular endothelial growth factor and tumor metastasis in uveal melanoma［J］.Int Eye Sci，2015，15(9)：1596-1599.
白惠玲，刘勤，文瑾，吴小玲.葡萄膜恶性黑色素瘤中血管内皮生长因子水平与肿瘤转移的关系［J］.国际眼科杂志，2015，15(9)：1596-1599.
［28］　LIU L，MA X.Prospect of Bevacizumab in treatment of iris neovascularization［J］.Rec Adv Ophthalmol，2010，30(5)：493-496.
刘琳，马翔.贝伐单抗在虹膜新生血管治疗中的应用［J］.眼科新进展，2010，30(5)：493-496.
［29］　YANG H，JAGER MJ，GROSSNIKLAUS HE.Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma［J］.Invest Ophthalmol Vis Sci，2010，51(6)：2835-2842.
［30］　SYED YY，MCKEAGE K.Aflibercept：a review in metastatic colorectal cancer［J］.Drugs，2015，75(12)：1435-1445.
［31］　TARHINI AA，FRANKEL P，MARGOLIN KA，CHRISTENSEN S，RUEL C，SHIPE-SPOTLOE J，et al.Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin［J］.Clin Cancer Res，2011，17(20)：6574-6581.
［32］　IBRAHIM N，YU Y，WALSH WR，YANG JL.Molecular targeted therapies for cancer：sorafenib mono-therapy and its combination with other therapies (review)［J］.Oncol Rep，2012，27(5)：1303-1311.
［33］　MANGIAMELI DP，BLANSFIELD JA，KACHALA S，LORANG D，SCHAFER PH，MULLER GW，et al.Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma［J］.J Transl Med，2007，5：38.
［34］　MOURIAUX F，SERVOIS V，PARIENTI JJ，LESIMPLE T，THYSS A，DUTRIAUX C，et al.Sorafenib in metastatic uveal melanoma：efficacy，toxicity and health-related quality of life in a multicentre phase II study［J］.Br J Cancer，2016，115(1)：20-24.
［35］　NIEDERKORN A，WACKERNAGEL W，ARTL M，SCHWANTZER G，AIGNER B，RICHTIG E.Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib［J］.Acta Ophthalmol，2014，92(8)：e696-697.
［36］　PEREIRA PR，ODASHIRO AN，MARSHALL JC，CORREA ZM，BELFORT R，BURNIER MN.The role of c-kit and imatinib mesylate in uveal melanoma［J］.J Carcinog，2005，4：19.
［37］　PENEL N，DELCAMBRE C，DURANDO X，CLISANT S，HEBBAR M，NEGRIER S，et al.O-Mel-Inib：a Cancero-pole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma［J］.Invest New Drugs，2008，26(6)：561-565.
［38］　MAHIPAL A，TIJANI L，CHAN K，LAUDADIO M，MASTRANGELO MJ，SATO T.A pilot study of sunitinib malate in patients with metastatic uveal melanoma［J］.Melanoma Res，2012，22(6)：440-446.
［39］　BARISIONE G，FABBI M，GINO A，QUEIROLO P，ORGIANO L，SPANO L，et al.Potential role of soluble c-Met as a new candidate biomarker of metastatic uveal melanoma［J］.JAMA Ophthalmol，2015，133(9)：1013-1021.
［40］　SURRIGA O，RAJASEKHAR VK，AMBROSINI G，DOGAN Y，HUANG R，SCHWARTZ GK.Crizotinib，a c-Met inhibitor，prevents metastasis in a metastatic uveal melanoma model［J］.Mol Cancer Ther，2013，12(12)：2817-2826.

相似文献/References:

[1]许瑶 曾骏文.近视眼药物治疗研究进展[J].眼科新进展,2013,33(7):000.
[2]李明 张永喜 王胜根.葡萄膜黑色素瘤术后自体细胞因子诱导的杀伤细胞治疗效果观察[J].眼科新进展,2012,32(8):000.
[3]冀向宁 牛广增.多灶性后极部视网膜色素上皮病变的激光与药物治疗[J].眼科新进展,2013,33(4):000.
[4]陈茜,吴尚操,谢汉平,等. 那他霉素滴眼液治疗真菌性角膜炎的多中心临床对照研究[J].眼科新进展,2014,34(4):371.[doi:10.13389/j.cnki.rao.2014.0102]
[5]王宇冉,孔晓路,靳中良,等.睫状环阻滞性青光眼的阶梯治疗临床分析[J].眼科新进展,2014,34(11):1065.[doi:10.13389/j.cnki.rao.2014.0295]
　WANG Yu-Ran,KONG Xiao-Lu,JIN Zhong-Liang,et al.Clinical analysis of ladder treatment in ciliary block glaucoma[J].Recent Advances in Ophthalmology,2014,34(2):1065.[doi:10.13389/j.cnki.rao.2014.0295]
[6]杨波,郁梅. 玻璃体内注射雷珠单抗治疗早产儿视网膜病变疗效观察[J].眼科新进展,2015,35(7):674.[doi:10.13389/j.cnki.rao.2015.0184]
　YANG Bo,YU Mei. Intravitreal injection of ranibizumab for retinopathy of prematurity[J].Recent Advances in Ophthalmology,2015,35(2):674.[doi:10.13389/j.cnki.rao.2015.0184]
[7]时毅,崔红平.角膜新生血管临床治疗的研究进展[J].眼科新进展,2016,36(11):1097.[doi:10.13389/j.cnki.rao.2016.0293]
　SHI Yi,CUI Hong-Ping.Research progress on clinical treatments of corneal neovascularization[J].Recent Advances in Ophthalmology,2016,36(2):1097.[doi:10.13389/j.cnki.rao.2016.0293]
[8]祁海燕,苏学刚.LncRNA MT1JP对葡萄膜黑色素瘤细胞迁移和侵袭的影响[J].眼科新进展,2017,37(6):531.[doi:10.13389/j.cnki.rao.2017.0134]
　QI Hai-Yan,SU Xue-Gang.Effects of LncRNA MT1JP on migration and invasion of uveal melanoma cells[J].Recent Advances in Ophthalmology,2017,37(2):531.[doi:10.13389/j.cnki.rao.2017.0134]
[9]李娜,曹娟,郁继国,等.miR-26a对葡萄膜黑色素瘤细胞增殖、凋亡、迁移和侵袭的影响及机制研究[J].眼科新进展,2017,37(7):619.[doi:10.13389/j.cnki.rao.2017.0157]
　LI Na,CAO Juan,YU Ji-Guo,et al.Effects of miR-26a on proliferation，apoptosis，migration and invasion of uveal melanoma cell and its mechanism[J].Recent Advances in Ophthalmology,2017,37(2):619.[doi:10.13389/j.cnki.rao.2017.0157]
[10]蒋依琳,高洪瑞.个体化综合治疗慢性移植物抗宿主病相关干眼的临床研究[J].眼科新进展,2017,37(10):958.[doi:10.13389/j.cnki.rao.2017.0243]
　JIANG Yi-Lin,GAO Hong-Rui.Individualized comprehensive medication for chronic graft-versus-host disease related severe dry eye disease[J].Recent Advances in Ophthalmology,2017,37(2):958.[doi:10.13389/j.cnki.rao.2017.0243]

备注/Memo

备注/Memo:
深圳市国际合作项目 (编号：GJHZ20160229170623135)
更新日期/Last Update: 2018-02-02